Why Did InspireMD Plunge 10.71% Despite FDA Approval?

InspireMD's stock price plummeted by 10.71% during pre-market trading on June 25, 2025, marking a significant decline for the medical device company.

InspireMD recently received FDA premarket approval (PMA) for its CGuard Prime carotid stent system, a pivotal development that is expected to drive the company's expansion in the U.S. market. This approval follows the submission of a PMA application in September 2024, and the company is now prepared for an immediate commercial launch.

InspireMD's stock has been under pressure due to broader market conditions and investor sentiment, but the recent FDA approval could provide a catalyst for a rebound in the coming weeks. The company's focus on innovative medical devices and its strategic initiatives are likely to be key factors in its future performance.